Mangoceuticals, Inc. Announces Pricing of Initial Public Offering
Mangoceuticals, Inc. has announced its initial public offering (IPO) of 1,250,000 shares at $4.00 each, generating gross proceeds of $5,000,000. The shares will commence trading on Nasdaq under the ticker symbol MGRX on March 21, 2023, with the offering expected to close on March 23, 2023. The company plans to utilize the funds for marketing its ED drug, 'Mango,' hiring personnel, software development, and general corporate purposes. Boustead Securities, LLC is the sole managing underwriter. A 45-day overallotment option for an additional 187,500 shares is also granted to underwriters.
- Initial public offering pricing set at $4.00 per share, generating $5,000,000.
- Funds will be used for marketing and operational expenses, indicating growth strategy.
- The offering could lead to shareholder dilution if the overallotment is exercised.
IPO Shares to Commence Trading Today on Nasdaq under Ticker Symbol "MGRX"
DALLAS, TX / ACCESSWIRE / March 21, 2023 / Mangoceuticals, Inc. ("MangoRx" or the "Company")(NASDAQ:MGRX), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of
The Company intends to use the net proceeds from the offering to finance the marketing and operational expenses associated with the planned marketing of its Mango ED product, to hire additional personnel to build organizational talent, to develop and maintain software, and for working capital and other general corporate purposes.
The shares are expected to begin trading on The Nasdaq Capital Market today, March 21, 2023, under the ticker symbol "MGRX." The offering is expected to close on March 23, 2023, subject to the satisfaction of customary closing conditions.
Boustead Securities, LLC is acting as the sole managing underwriter for the offering.
A registration statement on Form S-1, as amended (File No. 333-269240), relating to these securities was filed with the Securities and Exchange Commission ("SEC") and was declared effective on March 20, 2023. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. In addition, a copy of the final prospectus may be obtained, when available, from Boustead Securities, LLC by way of emailing requests to offerings@boustead1828.com or by calling 1-949-502-4408 or by standard mail to Boustead Securities, LLC, Attention: Equity Capital Markets, 6 Venture, Suite 395, Irvine, California 92618.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Mangoceuticals, Inc.
Mangoceuticals, Inc. is a company focused on developing, marketing and selling a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name "Mango" (think "Man Go"). For more information, please visit www.MangoRx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and the MangoRx brand and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the offer and sale of shares, the terms of the offering, the timing of the listing of the Company's securities on the Nasdaq Capital Market, the timing of the closing of the offering, the Company's ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of COVID-19, the demand for the Company's products and the Company's customers' economic condition, the impact of competitive products and pricing, general economic conditions and other risk factors detailed in the "Risk Factors" section and elsewhere in the Company's prospectus relating to the offering filed with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.
CONTACT INFORMATION:
FOR MEDIA AND INVESTOR RELATIONS
Fraxon Market Initiatives, LLC
Frank Benedetto
Phone: 619-915-9422
Email: investors@mangorx.com
For Underwriter Inquiries
Boustead Securities, LLC
Keith Moore, CEO
Phone: 949-502-4408
Email: keith@boustead1828.com
SOURCE: Mangoceuticals Inc.
View source version on accesswire.com:
https://www.accesswire.com/744197/Mangoceuticals-Inc-Announces-Pricing-of-Initial-Public-Offering
FAQ
What is the IPO price for Mangoceuticals (MGRX)?
When did Mangoceuticals start trading on Nasdaq?
What will Mangoceuticals use the proceeds from the IPO for?
How many shares has Mangoceuticals offered in its IPO?
What is the ticker symbol for Mangoceuticals on Nasdaq?
